For over three days, speakers and attendees were treated to discussions around:
Scroll below to see what you missed, or click here for a personalized SCOPE recap.
While over 11 subjects were covered, topics that dominated the discourse outside of sessions included: news around Tufts decentralized research, new FDA guidance on digital health devices, the entrance of retail pharmacy into clinical research, and connected data strategies.
Fresh off its recent press announcements with CVS Health and Tufts, Medable helped lead some of these conversations - proving the effectiveness of decentralized trials and their patient-centric approaches. Medable, which was recently named the leader in decentralized clinical trials by Everest also launched its Medable Partner Network at SCOPE 2022, showcasing the value of organizations who join forces to bring patient-centric approaches to patients faster than ever before.
Many sponsors were enthusiastic about the first-ever Tufts CSDD analysis on DCT, which models how DCTs can reduce clinical trial timelines and achieve net financial benefits ranging from five to 13 times for Phase II and Phase III trials.
Looking to learn more about Tuft’s recent research on DCTs? Click here.
CVS Health's recent announcement into the world of clinical research was widely discussed. Many in attendance believe that retail pharmacies will help unlock access to clinical research studies for millions of Americans.
Several sponsors referenced the new FDA guidance around DHT, discussing how best to ensure organizations reduce the burden on patients and sites while showcasing the value of their data.
Sponsors and CROs like Novartis, Sanofi, and PPD stressed the importance of developing a connected, patient-centric strategy at scale that offers better insights and enables better decision making.